Pathologic characterization and chemoresponsiveness to adriamycin of moloney sarcoma virus-induced osteosarcoma in the rat /

Pathologic characterization and chemoresponsiveness to adriamycin of moloney sarcoma virus-induced osteosarcoma in the rat /

Bibliographic Details
Main Author:	Olson, Harry Marshall
Language:	English
Published:	The Ohio State University / OhioLINK 1977
Subjects:	Biology Osteosarcoma Doxorubicin Tumors
Online Access:	http://rave.ohiolink.edu/etdc/view?acc_num=osu1487955360601357

Similar Items

Application of tumor-targeting peptide-decorated polypeptide nanoparticles with doxorubicin to treat osteosarcoma
by: Renna Qiu, et al.
Published: (2020-01-01)

The Sensitization of Melatonin in Osteosarcoma Cells by Suppression of Anti-Apoptotic Proteins
by: Seyed Mostafa Mir, et al.
Published: (2020-06-01)

Effects of dexrazoxane on doxorubicin-related cardiotoxicity and second malignant neoplasms in children with osteosarcoma: a report from the Children’s Oncology Group
by: Lisa M. Kopp, et al.
Published: (2019-10-01)

Role of Topoisomerases in Pediatric High Grade Osteosarcomas: TOP2A Gene Is One of the Unique Molecular Biomarkers of Chemoresponse
by: Natacha Entz-Werle, et al.
Published: (2013-06-01)

Hippo/YAP signaling pathway is involved in osteosarcoma chemoresistance
by: Dong-Yu Wang, et al.
Published: (2016-05-01)

Small Nucleolar RNAs Determine Resistance to Doxorubicin in Human Osteosarcoma
by: Martina Godel, et al.
Published: (2020-06-01)

Development, Characterization and Cell Viability Inhibition of PVA Spheres Loaded with Doxorubicin and 4′-Amino-1-Naphthyl-Chalcone (D14) for Osteosarcoma
by: Viviane Seba, et al.
Published: (2021-08-01)

The effects of taurolidine alone and in combination with doxorubicin or carboplatin in canine osteosarcoma <it>in vitro</it>
by: Marley Kevin, et al.
Published: (2013-01-01)

The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma
by: Hye Jeong Park, et al.
Published: (2018-05-01)

β-Elemene Enhances the Sensitivity of Osteosarcoma Cells to Doxorubicin via Downregulation of Peroxiredoxin-1
by: Zhang S, et al.
Published: (2021-06-01)

A Novel Approach on Drug Delivery: Investigation of A New Nano-Formulation of Liposomal Doxorubicin and Biological Evaluation of Entrapped Doxorubicin on Various Osteosarcoma Cell Lines
by: Fateme Haghiralsadat, et al.
Published: (2017-05-01)

A Nanodrug Consisting Of Doxorubicin And Exosome Derived From Mesenchymal Stem Cells For Osteosarcoma Treatment In Vitro
by: Wei H, et al.
Published: (2019-11-01)

In Vitro Delivery and Controlled Release of Doxorubicin for Targeting Osteosarcoma Bone Cancer
by: Tengku Azmi Tengku Ibrahim, et al.
Published: (2013-08-01)

Light-Responsive Micelles Loaded With Doxorubicin for Osteosarcoma Suppression
by: Jiayi Chen, et al.
Published: (2021-06-01)

The efficacy and safety comparison of first-line chemotherapeutic agents (high-dose methotrexate, doxorubicin, cisplatin, and ifosfamide) for osteosarcoma: a network meta-analysis
by: Bin Zhang, et al.
Published: (2020-02-01)

Hypoxia promotes drug resistance in osteosarcoma cells via activating AMP-activated protein kinase (AMPK) signaling
by: Changfu Zhao, et al.
Published: (2016-03-01)

Inhibition of SIRT6 potentiates the anti-tumor effect of doxorubicin through suppression of the DNA damage repair pathway in osteosarcoma
by: Zhongkai Zhang, et al.
Published: (2020-11-01)

Doxorubicin and Edelfosine Combo-Loaded Lipid–Polymer Hybrid Nanoparticles for Synergistic Anticancer Effect Against Drug-Resistant Osteosarcoma
by: Yang P, et al.
Published: (2020-08-01)

TFAP2C-mediated LINC00922 signaling underpins doxorubicin-resistant osteosarcoma
by: Zenghui Gu, et al.
Published: (2020-09-01)

Osteosarcoma costal
by: Manuel José Luque
Published: (1944-09-01)

Targeting Molecular Mechanisms Underlying Treatment Efficacy and Resistance in Osteosarcoma: A Review of Current and Future Strategies
by: Ingrid Lilienthal, et al.
Published: (2020-09-01)

Chlorogenic Acid Enhances Doxorubicin-Mediated Cytotoxic Effect in Osteosarcoma Cells
by: Alessia Salzillo, et al.
Published: (2021-08-01)

Long non-coding RNA LINC00426 contributes to doxorubicin resistance by sponging miR-4319 in osteosarcoma
by: Lulin Wang, et al.
Published: (2020-07-01)

Assessment of the Nutraceutical Effects of Oleuropein and the Cytotoxic Effects of Adriamycin, When Administered Alone and in Combination, in MG-63 Human Osteosarcoma Cells
by: Katerina Gioti, et al.
Published: (2021-01-01)

Osteosarcoma telangiectásico en un lactante
by: María de los Ángeles Cepeda, et al.
Published: (2017-01-01)

Chemotherapy in the management of periosteal osteosarcoma: A narrative review
by: Tarek Assi, et al.
Published: (2021-10-01)

Osteosarcoma mandibular
by: Daniel A. Carretero Ancelmo, et al.
Published: (2011-07-01)

Co-delivery of doxorubicin and paclitaxel by reduction/pH dual responsive nanocarriers for osteosarcoma therapy
by: Yongshuang Li, et al.
Published: (2020-01-01)

Apoptosis and remodeling in adriamycin-induced cardiomyopathy rat model
by: Young Mi Hong, et al.
Published: (2017-11-01)

Osteosarcoma: a comprehensive review
by: Misaghi Amirhossein, et al.
Published: (2018-01-01)

Pioglitazone, an agonist of PPARγ, reverses doxorubicin-resistance in an osteosarcoma patient-derived orthotopic xenograft model by downregulating P-glycoprotein expression
by: Takashi Higuchi, et al.
Published: (2019-10-01)

Osteosarcoma of the jaws: A retrospective study
by: Baghaie F, et al.
Published: (2003-06-01)

Osteosarcoma of the jaws: A retrospective study
by: Baghaie F, et al.
Published: (2003-06-01)

Osteosarcoma of the Maxilla: A Rare Case with Unusual Clinical Presentation
by: Pouyan Amini Shakib, et al.
Published: (2013-08-01)

Circ_0001721 enhances doxorubicin resistance and promotes tumorigenesis in osteosarcoma through miR-758/TCF4 axis
by: Huapeng Guan, et al.
Published: (2021-07-01)

Inhibition of KLF4 by Statins Reverses Adriamycin-Induced Metastasis and Cancer Stemness in Osteosarcoma Cells
by: Yangling Li, et al.
Published: (2017-06-01)

SOX2OT variant 7 contributes to the synergistic interaction between EGCG and Doxorubicin to kill osteosarcoma via autophagy and stemness inhibition
by: Wanchun Wang, et al.
Published: (2018-02-01)

Primary Osteosarcoma of the Breast in Young Women: One Case Report and Literature Review
by: Xuefeng BAI, et al.
Published: (2009-08-01)

OSTEOSARCOMA
by: Stephanie Paola Hernández, et al.
Published: (2021-04-01)

Development of an immune-related prognostic index associated with osteosarcoma
by: Chao-Dong Yin, et al.
Published: (2021-01-01)